| Name | Title | Contact Details |
|---|---|---|
Adrian Schreyer |
Chief Technology Officer | Profile |
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.
Diassess Inc. is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health.
Genome Sciences Centre is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Polar Electro Inc is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alberta Conservation Association is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.